Compare Global Payments Inc (GPN) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs Heron Therapeutics Inc — how do they compare? Global Payments Inc trades at $82.03 (market cap $21.46B), while Heron Therapeutics Inc trades at $0.4 (market cap $68.01M). The key difference: Global Payments Inc is far larger — about 315.5× Heron Therapeutics Inc's market cap, and Global Payments Inc pays a 1.23% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global Payments Inc for 50 Days and Heron Therapeutics Inc for 35 Days on average.
| GPN | HRTX | |
|---|---|---|
Market Cap | $21.46B | $68.01M |
Volume | 1,482,600 | 1,891,941 |
Sector | Financials | Health |
52-Week High | $94.83 | $1.49 |
52-Week Low | $62.47 | $0.27 |
Typical Hold Time | 50 Days | 35 Days |
Enterprise Value | $39.60B | $174.75M |
Dividend Yield | 1.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $82.20, up 1.38% on the day, with a neutral technical signal and bullish moving averages. The stock has beaten EPS estimates for three consecutive quarters, though Q3 2026 results are pending. Revenue declined to $7.71B in 2025, but net income margin improved to 18.16%. Analyst consensus is bullish with a $102.75 price target, representing significant upside. Recent news highlights growth initiatives like the Genius platform and Worldpay integration.
GPN offers potential upside based on strong analyst sentiment and strategic initiatives, but faces risks from rising costs, high debt levels, and competitive pressures. The negative net income margin projection for 2026 underscores execution challenges. Investors should weigh the company's digital payment growth against macroeconomic and operational headwinds.
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
